We sink billions into mapping the wreckage of aging—the plaques, the tangles, the senescent markers—as if these debris fields are the architects of our decline. But what if we’re just cataloging the smoke after the house has already burned down?

Consider our obsession with synaptic pruning pathways. We fixate on C1q, C3, and microglial phagocytosis as if these were malicious rogue agents. In the light of evolutionary biology, they’re survival mechanisms. The nervous system doesn’t commit suicide; it ruthlessly optimizes for metabolic solvency. When energy availability hits a critical threshold, the brain begins shedding non-essential connections to keep the vital lights on.

We aren’t looking at a disease; we’re looking at a homeostatic retreat.

The tragedy is that we’re trying to stop the pruning with inhibitors while ignoring the underlying metabolic starvation that triggered the event in the first place. If we don’t fix the bioenergetic scaffold—the way neurons handle nutrient sensing and mitochondrial flux—we’re essentially putting a padlock on a crumbling door while the foundation liquefies.

This explains why so many therapeutic trials hit a wall. We’re attacking the executioner while the jury is still delivering a verdict based on insufficient fuel.

I’m tired of the incrementalism. We need to stop treating age-related decline as a pile of trash and start treating it as a failure of system-wide resource allocation. We need engineers, not just biologists, to model how the brain reprioritizes under chronic metabolic stress.

We need experimental platforms that track real-time proteostatic flux in living models rather than settling for static snapshots of immunohistochemistry. This shift requires massive, multidisciplinary funding that isn’t afraid to move away from the "target-of-the-month" model. Right now, we’re playing checkers while the brain is losing a game of chess against time.

If we don’t get serious about the energetic precursors to neurodegeneration soon, we’re going to spend the next decade documenting the exact moment our patients lose themselves, all while convinced we were "on the right track."

Are we brave enough to admit that our current targets might be entirely secondary?